LIPID METABOLISM AND/OR SUGAR METABOLISM IMPROVER CONTAINING LACTIC ACID BACTERIUM OR TREATMENT PRODUCT THEREOF
This invention provides the use of a microorganism capable of improving both lipid metabolism and sugar metabolism. Specifically, the invention relates to: a lipid metabolism and/or sugar metabolism improver comprising, as an active ingredient, a bacterial cell selected from bacteria belonging to the genus Lactobacillus and the genus Bifidobacterium , a treated product of the bacterial cell, or a mixture thereof, having dual-agonistic activities to peroxisome proliferator activated receptor (PPAR)α and peroxisome proliferator activated receptor (PPAR)γ; to a food or a beverage comprising the improver; and to a pharmaceutical composition comprising the improver.
1 . A bacterial cell or a treated product thereof having dual-agonistic activities on a peroxisome proliferator activated receptor (PPAR)α and a peroxisome proliferator activated receptor (PPAR)γ.
2 . The bacterial cell or the treated product thereof according to claim 1 , wherein the PPARα activity is 70 or more relative to negative control activity of 0 and positive control activity of 100 as measured by PPARα reporter assay and the PPARγ ligand activity shows positive exceeding 0 relative to negative control activity of 0 and positive control activity of 100 as measured by PPARγ reporter assay.
3 . The bacterial cell or the treated product thereof according to claim 1 or 2 , wherein the bacterial cell belongs to Lactobacillus amylovorus, Lactobacillus gasseri, Bifidobacterium infantis, Bifidobacterium adolescentis , or Bifidobacterium breve.
4 . The bacterial cell or the treated product thereof according to any one of claims 1 to 3 , wherein the bacterial cell is Lactobacillus amylovorus CP1563 strain (Accession Number FERM BP-11255) or Lactobacillus amylovorus CP1562 strain (Accession Number FERM BP-11379) or a mutant or bred strain thereof, or a mutant or bred strain of Lactobacillus gasseri CP2305 strain (Accession Number FERM BP-11331).
5 . The treated product of bacterial cell according to any one of claims 1 to 4 , which is a destructed product of the bacterial cell, an extracted product of the bacterial cell, or a dried product thereof.
6 . A lipid metabolism and/or sugar metabolism improver comprising, as an active ingredient, a bacterial cell, a treated product thereof, or a mixture thereof having dual-agonistic activities on a peroxisome proliferator activated receptor (PPAR)α and a peroxisome proliferator activated receptor (PPAR)γ.
7 . A lipid metabolism and/or sugar metabolism improver comprising, as an active ingredient, a bacterial cell selected from bacteria belonging to the genus Lactobacillus and the genus Bifidobacterium , a treated product thereof, or a mixture thereof having dual-agonistic activities on a peroxisome proliferator activated receptor (PPAR)α and a peroxisome proliferator activated receptor (PPAR)γ.
8 . The lipid metabolism and/or sugar metabolism improver according to claim 6 or 7 , wherein the PPARα activity is 70 or more relative to negative control activity of 0 and positive control activity of 100 as measured by PPARα reporter assay and the PPARγ ligand activity shows positive exceeding 0 relative to negative control activity of 0 and positive control activity of 100 as measured by PPARγ reporter assay.
9 . The lipid metabolism and/or sugar metabolism improver according to any one of claims 6 to 8 , wherein the bacterial cell belongs to Lactobacillus amylovorus, Lactobacillus gasseri, Bifidobacterium infantis, Bifidobacterium adolescentis , or Bifidobacterium breve.
10 . The lipid metabolism and/or sugar metabolism improver according to any one of claims 6 to 9 , wherein the bacterial cell is Lactobacillus amylovorus CP1563 strain (Accession Number FERM BP-11255) or Lactobacillus amylovorus CP1562 strain (Accession Number FERM BP-11379), Lactobacillus gasseri CP2305 strain (Accession Number FERM BP-11331), or a mutant or bred strain thereof.
11 . The lipid metabolism and/or sugar metabolism improver according to any one of claims 6 to 10 , wherein the treated product of bacterial cell is a destructed product of the bacterial cell, an extracted product of the bacterial cell, or a dried product thereof.
12 . The lipid metabolism and/or sugar metabolism improver according to any one of claims 6 to 11 , which further comprises a carrier or an excipient used for foods or beverages or pharmaceutical drugs.
13 . A food or beverage comprising the lipid metabolism and/or sugar metabolism improver according to any one of claims 6 to 12 as a food additive.
14 . The food or beverage according to claim 13 , which is a functional food or health food for use in improving the lipid metabolism and/or sugar metabolism.
15 . A pharmaceutical composition for use in preventing, improving, or treating a lipid metabolism disorder and/or sugar metabolism disorder, comprising, as an active ingredient, the lipid metabolism and/or sugar metabolism improver according to any one of claims 6 to 12 .
16 . A process for producing a food or beverage having a lipid metabolism and/or sugar metabolism improving effect, comprising adding the lipid metabolism and/or sugar metabolism improver according to any one of claims 6 to 12 to a food or beverage.
17 . Use of Lactobacillus amylovorus CP1563 strain (Accession Number FERM BP-11255), Lactobacillus amylovorus CP1562 strain (Accession Number FERM BP-11379), Lactobacillus gasseri CP2305 strain (Accession Number FERM BP-11331), or a mutant or bred strain thereof, a treated product thereof, or a mixture thereof in the production of the lipid metabolism and/or sugar metabolism improver according to any one of claims 6 to 12 .
18 . Lactobacillus amylovorus CP1563 strain (Accession Number FERM BP-11255) or Lactobacillus amylovorus CP1562 strain (Accession Number FERM BP-11379), or a mutant or bred strain thereof, or a mutant or bred strain of Lactobacillus gasseri CP2305 strain (Accession Number FERM BP-11331) for use in imparting a lipid metabolism and sugar metabolism improving action.
19 . Lactobacillus amylovorus CP1563 strain (Accession Number FERM BP-11255) or Lactobacillus amylovorus CP1562 strain (Accession Number FERM BP-11379) or a mutant or bred strain thereof, or a mutant or bred strain of Lactobacillus gasseri CP2305 strain (Accession Number FERM BP-11331).
20 . The bacterial cell or the treated product thereof according to claim 1 or 2 , wherein the bacterial cell belongs to the genus Lactobacillus or the genus Bifidobacterium.
21 . Use of the bacterial cell or the treated product thereof according to any one of claims 1 to 5 for use in the production of a composition for improving lipid metabolism and/or sugar metabolism.
22 . Use of the bacterial cell or the treated product thereof according to any one of claims 1 to 5 for use in the production of a composition for preventing lipid metabolism and/or sugar metabolism.
23 . The bacterial cell or the treated product thereof according to any one of claims 1 to 5 for use in the production of a composition for improving lipid metabolism and/or sugar metabolism.
24 . The bacterial cell or the treated product thereof according to any one of claims 1 to 5 for use in the production of a composition for preventing lipid metabolism and/or sugar metabolism.
25 . The bacterial cell or the treated product thereof according to any one of claims 1 to 5 for use in the production of a composition for reducing subcutaneous fat and/or visceral fat.
26 . The bacterial cell or the treated product thereof according to any one of claims 1 to 5 for use in the production of a composition for preventing accumulation of subcutaneous fat and/or visceral fat.